| Date | Title | | | 11/11/08 | Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia Program| Reduction in Tachycardia and Blood Acetaldehyde Levels in Subset
of Subjects with Inborn Error of Alcohol Metabolism
Novato, California, Nov 11, 2008 – Raptor Pharmaceuticals Corp. (“Raptor” or the “Company”) (OTC Bulletin Board: RPTP), today announced positive results in its Phase IIa study of oral 4-methylpyrazole (“4-MP”) in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development stage of its Convivia™ program. Convivia™ is Raptor’s proprietary oral formulat... |
|  | | 11/10/08 | Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease|
Novato, California, November 10, 2008 -
Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that the Company has entered into an agreement with the Centre Hospitalier Universitaire d'Angers ("CHU d'Angers") of France to evaluate Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in a Phase II clinical trial in patients with Huntington's Disease ("Huntington's"). CHU d'Angers has received a grant from the... |
| | | 11/06/08 | Raptor Pharmaceuticals Provides Update on Targeting Platforms|
Enters Collaboration on Receptor Associated Protein (RAP)
Supports NeuroTrans™ Platform with Japanese Patent
Novato, California, November 6, 2008 -
Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced updates on its preclinical program which utilizes drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins. The Company signed a collaborative research agreement with the Brigham and Wo... |
| | | 10/29/08 | Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare Conferences|
-->
Novato, California, October 29, 2008 -
Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP), today announced that senior management will present a corporate overview and clinical pipeline updates at two upcoming healthcare investor conferences:
The 7th Annual BIO Investor Forum, to be held October 29-31, 2008 at the Palace Hotel in San Francisco, CA. Raptor's presentation will take place on Wednesday, October 29 at 4:45pm ET (1:45pm PT) in Telegraph Hill. A live audi... |
| | | 10/20/08 | Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)|
Commences Patient Dosing of Delayed-Release Cysteamine in Collaboration with UC, San Diego
Novato, California, October 20, 2008 -
Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced the initiation of patient dosing in a Phase 2a clinical trial, in collaboration with the University of California, San Diego ("UCSD"), to evaluate cysteamine bitartrate ("cysteamine") in adolescents diagnosed with Non-alcoholic Steatohepatitis ("NASH")... |
| | | 07/16/08 | Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease|
Raptor to Support Phase 2a Clinical Trial at UCSD
Novato, California, July 16, 2008 - Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced the execution of a collaboration agreement (the "Agreement") with the University of California, San Diego ("UCSD") to include a Phase 2a clinical trial to evaluate a delayed-release preparation of cysteamine bitartrate ("Cysteamine") in adolescents diagnosed with Non-Alcoholic Steatohepatitis... |
| | | 07/14/08 | Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board|
Novato, California, July 14, 2008 - Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP), today announced the appointments of Richard L. Franklin, M.D., Ph.D. to the Company's board of directors and Stephen C. Blacklow, M.D., Ph.D. to its scientific advisory board.
Christopher M. Starr, Ph.D., co-founder and CEO of Raptor Pharmaceuticals Corp, stated, "I would like to welcome Drs. Franklin and Blacklow as valuable additions to our board of directors and scientific adviso... |
| | | 06/30/08 | Raptor Pharmaceuticals Closes $10 Million Private Placement| Novato, California, June 30, 2008 - Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP), today announced that it raised U.S.$10 million through a private placement of 20 million units constituting an aggregate of 20 million shares of the Company's common stock and two-year warrants to purchase 10 million shares of common stock. After deducting placement agent fees, the Company raised $9.3 million in net proceeds from the private placement. The Company intends to use the net proceeds to... |
| | | 06/23/08 | Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008|
Cystinosis Foundation Ireland to Host Event June 27-28, 2008
Novato, California, June 23, 2008 - Raptor Pharmaceuticals Corp. (Raptor or the Company) (OTC Bulletin Board: RPTP), today announced that Ted Daley, President of Raptor’s clinical division, will present at the Cystinosis Foundation Ireland’s 5th International Cystinosis Conference to be held June 27-28, 2008 at the Hilton Hotel, Dublin City, Charlemont Place, Dublin 2, in Dublin, Ireland.
World experts in the ... |
| | | 06/12/08 | Raptor Pharmaceuticals Corp. to Present at BIO 2008 International Convention|
Novato, California, June 12, 2008 - Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP), today announced that Ted Daley, President of Bennu Pharmaceuticals Inc., Raptor's clinical development subsidiary, will present at the 2008 BIO International Convention to be held June 17 - 20, 2008 at the San Diego Convention Center in San Diego, CA.
Mr. Daley's 15-minute corporate overview will take place on Wednesday, June 18, 2008 at 1:15p.m. (PT) in room 4 of the CNS/Neurology ... |
| | | 06/09/08 | Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease|
Potential Efficacy in Huntington's Disease Already Demonstrated
Novato, California, June 9, 2008 – Raptor Pharmaceuticals Corp. (“Raptor” or the “Company”) (OTC Bulletin Board: RPTP), today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for cysteamine bitartrate (“cysteamine”) for the treatment of Huntington's disease (“HD”). Cysteamine is currently approved by the FDA and European Medicines Agency (“EMEA”) to treat nephropathic cyst... |
| | | 04/21/08 | Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study For Convivia™|
Patient Dosing Underway in Company's First Clinical Program
Novato, California, April 21, 2008 – Raptor Pharmaceuticals Corp. (“Raptor” or the “Company”) (OTC Bulletin Board: RPTP), today announced that its clinical development subsidiary, Bennu Pharmaceuticals Inc. (“Bennu”), has initiated the Company's first clinical-stage program after dosing the first cohort in a Phase IIa study of oral 4-methylpyrazole (“4-MP”) in subjects with ALDH2 deficiency, or ethanol intolerance, as the... |
| | | 03/19/08 | Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline|
Acquires Rights from UCSD to Develop Cysteamine for the Treatment of NASH
Enters Convivia™ Formulation and Manufacturing Agreement with Patheon Pharmaceuticals
Novato, California, March 19, 2008– Raptor Pharmaceuticals Corp. (“Raptor” or the “Company”) (OTC Bulletin Board: RPTP), today announced that its clinical development subsidiary, Bennu Pharmaceuticals Inc. (“Bennu”), has acquired an exclusive worldwide license to intellectual property from the University of California, San... |
| |
|
